The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 15, 2022

Filed:

May. 22, 2017
Applicant:

The University of Chicago, Chicago, IL (US);

Inventors:

Wenbin Lin, Chicago, IL (US);

Xiaopin Duan, Guangzhou, CN;

Christina Chan, Chicago, IL (US);

Wenbo Han, Chicago, IL (US);

Assignee:

The University of Chicago, Chicago, IL (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/66 (2006.01); A61K 47/54 (2017.01); A61P 35/00 (2006.01); A61K 9/127 (2006.01); A61K 31/337 (2006.01); A61K 31/357 (2006.01); A61K 31/7048 (2006.01); A61K 31/704 (2006.01); A61K 31/136 (2006.01); A61K 31/7068 (2006.01); A61K 31/4745 (2006.01); C12N 15/11 (2006.01); A61K 31/475 (2006.01); A61K 9/51 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 31/66 (2013.01); A61K 9/1277 (2013.01); A61K 9/51 (2013.01); A61K 31/136 (2013.01); A61K 31/337 (2013.01); A61K 31/357 (2013.01); A61K 31/475 (2013.01); A61K 31/4745 (2013.01); A61K 31/704 (2013.01); A61K 31/7048 (2013.01); A61K 31/7068 (2013.01); A61K 47/543 (2017.08); A61P 35/00 (2018.01); C12N 15/111 (2013.01); A61K 45/06 (2013.01); C12N 2310/11 (2013.01); C12N 2310/14 (2013.01); C12N 2310/141 (2013.01); C12N 2320/32 (2013.01);
Abstract

Prodrugs containing lipid moieties attached to drug derivatives, such as anti-cancer drug derivatives, via linkers comprising disulfide groups are described. Also described are nanoparticles coated with a lipid layer containing the prodrugs, formulations comprising the nanoparticles, and the use of the nanoparticles in methods of treating diseases, such as cancer, alone or in combination with additional drug compounds, targeting agents, and/or immunotherapy agents, such as immunosuppression inhibitors that target the CTLA-4, PD-1/PD-L1, IDO, LAG-3, CCR-7 or other pathways, or multiple immunosuppression inhibitors targeting a combination of such pathways. Optionally, the nanoparticles can comprise a photosensitizer or a derivative thereof and can be used in methods involving photodynamic therapy. Synergistic therapeutic effects result from combinations of multiple modalities provided by the disclosed nanoparticles and/or nanoparticle formulations.


Find Patent Forward Citations

Loading…